Answers are grounded in this paper and cite their sources.
The National Cholesterol Education Program’s Third Adult Treatment Panel guidelines recommend that low-density lipoprotein cholesterol should be the primary target of lipidlowering treatments, followed by non-high-density lipoprotein-cholesterol as a secondary target that represents the dyslipidemia of insulin resistance. A growing body of evidence suggests that this may not be the optimal approach. Alternative risk markers and decisionmaking approaches for the management of lipid-associated risk are discussed in the context of current evidence, clinical applicability, cost–effectiveness and future trends in the practice of preventive medicine.
No takes yet. Share an insight, caveat, or question.
Stanley H. Hsia (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: